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Dear Editor,
Lenalidomide has emerged as standard treatment for 5q-
syndrome [1]. In normal cell cultures, lenalidomide
enhances T cell proliferation [2], and in cells isolated from
HIV-positive (HIV+) and CMV+ patients, lenalidomide
enhances CD8+ cytotoxic T cell activity against viral
antigens [3]. There are no in vivo data on lenalidomide in
HIV+ patients.
We are reporting on a 52-year-old HIV+ patient with an
undetectable viral load for the past 10 years on combined
antiretroviral therapy (cART) who developed 5q-syndrome
and was successfully treated with lenalidomide. In 1989, he
was diagnosed with HIV and had been on cART since 1996
after mono- and bi-therapies. He had suffered and recovered
from multiple complications (CMV-retinitis, Kaposi sar-
coma, cryptococcal meningitis, oesophageal candidiasis,
disseminated Mycobacterium genavense infection and anal
squamous cell carcinoma (T1N0M0)). In February 2007,
persistent pancytopenia and dependency on red blood cell
transfusions for a month motivated a bone marrow (BM)
biopsy revealing a 5q-syndrome (karyotype: 46,XY,del(5)
(q13-14q33)[7]/46,XY[3]). In August 2007 lenalidomide
was started (10 mg for 21 days every 28 days) according to
recommendations on the use of lenalidomide in MDS with-
out dose reduction at any time [4]. He became transfusion
independent 18 days after treatment start. After two cycles,
complete normalisation of peripheral blood counts was
achieved (Fig. 1), and phlebotomy therapy was initiated for
iron overload. After five cycles, BM examination revealed
complete cytological and partial cytogenetic remission (5q
deletion in eight of 50 metaphases). HIV viral load
remained undetectable before lenalidomide and 1, 2, 3, 4,
8, 12 and 24 weeks after the start of lenalidomide.
CD4+ cells had reached a steady state between 137
and 206 cells/mm3 before lenalidomide. They rose to
235 cells/mm3 2 months after starting lenalidomide and
remained stable between 230 and 240 cells/mm3. CD8+
cells were between 314 and 393 cells/mm3 before and
reached stable levels over 500 cells/mm3 6 weeks after
treatment began (527–1,195 cells/mm3). Lymphocyte
counts rose from 0.9 to 1×109/l to stable levels between
1.2 and 2.5×109/l 3 months after treatment was initiated
(Figs. 1 and 2).
Before lenalidomide treatment, plasma concentrations of
atazanavir (ATV) and lopinavir (LPV) were 1,767 and
13,903 ng/ml 5 h after last drug intake. On days 23 and 28
of cycle2 of lenalidomide treatment, plasma levels 11.5 h
after last drug intake were 2,728 and 2,180 ng/ml for ATV
and 7,728 and 5,791 ng/ml for LPV, respectively. At day20
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of cycle3, ATV and LPV plasma concentrations were 2,370
and 8,378 ng/ml 11.75 h after last drug intake.
This is the first report on lenalidomide administration to
an HIV+ patient with 5q-syndrome without interruption of
cART. Plasma levels of ATV under lenalidomide treatment
were slightly increased (changing from percentile 40 to 80
in the reference pharmacokinetics curve), whereas plasma
concentrations of LPV were not affected. Follow-up
examination of CD4+ cells as well as HIV viral load did
not demonstrate a negative impact of lenalidomide. On the
contrary, CD4+ cells showed a tendency to rise to stable
levels over 230 cells/mm3. The CD4+ cell rise might be due
to the fact that lymphocytes could have been part of the
MDS clone. Another reason could be an immunomodula-
tory effect. No rise in viral load was observed, as
demonstrated in patients treated with thalidomide [5, 6].
Although a 5q-syndrome rarely occurs in HIV+ patients,
our observation is of interest as it suggests that HIV+
patients with other pathologies known to respond to
lenalidomide, such as multiple myeloma for instance, could
also benefit from this treatment. As thalidomide has proven
to be helpful in HIV+ patients for wasting syndrome, ulcers
and Kaposi's sarcoma but is sometimes impossible to
continue due to adverse events, lenalidomide could also
be an alternative treatment in these diseases.
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Fig. 2 Changes in CD4 and total lymphocyte counts
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Fig. 1 Changes in haemoglobin, thrombocytes and CD4 counts
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